Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(88 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(267 productos)
Mostrar 6 subcategorías más
Se han encontrado 1483 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Mutated EGFR-IN-2
CAS:Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64BGB659
CAS:<p>BGB659 is effective inhibitor of RAF.</p>Fórmula:C29H29F3N4O3Pureza:98%Forma y color:SolidPeso molecular:538.56PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Fórmula:C27H39N9OForma y color:SolidPeso molecular:505.66EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51VEGFR-2-IN-28
CAS:<p>VEGFR-2-IN-28 is a potent inhibitor of VEGFR-2 (IC50: 0.83 μM). VEGFR-2-IN-28 induces apoptosis and exhibits antitumor effects.</p>Fórmula:C26H17N7O7Forma y color:SolidPeso molecular:539.46KRCA-0713
CAS:<p>KRCA-0713 is a ALK inhibitor.</p>Fórmula:C26H32ClN5O3SPureza:98%Forma y color:SolidPeso molecular:530.08FGFR3-IN-5
CAS:<p>FGFR3-IN-5: potent, selective FGFR3 inhibitor. IC50: 3 nM FGFR3, 44 nM FGFR2, 289 nM FGFR1. For cancer research.</p>Fórmula:C24H24FN7O3Forma y color:SolidPeso molecular:477.49S116836
CAS:<p>S116836 is a tyrosine kinase inhibitor.</p>Fórmula:C27H21F3N6OPureza:98%Forma y color:SolidPeso molecular:502.49JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58CGI560
CAS:<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Fórmula:C29H27N5OForma y color:SolidPeso molecular:461.56FAK inhibitor 5
CAS:<p>FAK inhibitor 5 is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.</p>Fórmula:C20H21N3O2SPureza:98%Forma y color:SolidPeso molecular:367.46PDGFRα kinase inhibitor 1
CAS:PDGFRα kinase inhibitor 1 is a type II PDGFRα kinase inhibitor that inhibits both PDGFRα and PDGFRβ.Fórmula:C34H34N8O2Pureza:99.78%Forma y color:SolidPeso molecular:586.69PDGFRα/FLT3-ITD-IN-2
CAS:<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Fórmula:C28H41N9OForma y color:SolidPeso molecular:519.68PD173952
CAS:<p>PD173952 is a Src kinase and Myt1 inhibitor with antitumor activity, inhibits Lyn, Abl and Csk, and induces Bcr-Abl-dependent hematopoietic cell apoptosis.</p>Fórmula:C24H21Cl2N5O2Pureza:99.5%Forma y color:SolidPeso molecular:482.36c-ABL-IN-2
CAS:<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Fórmula:C21H20N4OForma y color:SolidPeso molecular:344.41KRC-108
CAS:<p>KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.</p>Fórmula:C20H20N6OForma y color:SolidPeso molecular:360.41Tyrphostin AG 568
CAS:<p>Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.</p>Fórmula:C13H9N5O2Pureza:98%Forma y color:SolidPeso molecular:267.24WB-308
CAS:<p>WB-308 is an EGFR inhibitor that acts by decreasing NSCLC cell proliferation and colony formation and causing G2/M arrest and apoptosis.</p>Fórmula:C19H17FN2OPureza:98%Forma y color:SolidPeso molecular:308.35Nuvenzepine
CAS:Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.Fórmula:C19H20N4O2Pureza:98%Forma y color:SolidPeso molecular:336.39Adhesamine
CAS:<p>Adhesamine, a dumbbell molecule, enhances cell adhesion, growth, neuron differentiation, and survival via MAPK/FAK.</p>Fórmula:C24H32Cl4N8O2S2Forma y color:SolidPeso molecular:670.51FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Forma y color:SolidPeso molecular:419.48EGFR/HER2/TS-IN-2
CAS:<p>EGFR/HER2/TS-IN-2: Strong EGFR, HER2 & TS inhibitor; EGFR IC50=0.173μM, HER2 IC50=0.125μM, TS IC50=1.12μM; kills MDA-MB-231 cells (IC50=1.69μM).</p>Fórmula:C26H21N7OS2Forma y color:SolidPeso molecular:511.62BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Fórmula:C24H31N5O4SPureza:98%Forma y color:SolidPeso molecular:485.6VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Fórmula:C26H21ClF3N5O3S2Forma y color:SolidPeso molecular:608.05YF-452
CAS:<p>YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.</p>Fórmula:C24H26BrN3OPureza:98%Forma y color:SolidPeso molecular:452.39SB-220025 trihydrochloride
CAS:<p>SB-220025 trihydrochloride is an effective and specific human p38 mitogen-activated protein kinase inhibitor.</p>Fórmula:C18H22Cl3FN6Pureza:98%Forma y color:SolidPeso molecular:447.77MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45Multi-kinase-IN-3
CAS:<p>Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).</p>Fórmula:C33H33N5O3Forma y color:SolidPeso molecular:547.65MAX-40279 hydrochloride
CAS:<p>MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.</p>Fórmula:C22H24ClFN6OSForma y color:SolidPeso molecular:474.98Con B-1
CAS:<p>ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .</p>Fórmula:C38H52ClN7O6SForma y color:SolidPeso molecular:770.38VEGFR-2-IN-30
<p>VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.</p>Fórmula:C28H23ClN6O4S2Forma y color:SolidPeso molecular:607.1PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56P505-15 Acetate
CAS:<p>P505-15 Acetate inhibits spleen tyrosine kinase, reduces immune response and inflammation, and lowers arthritis severity.</p>Fórmula:C21H27N9O3Pureza:99.99%Forma y color:SolidPeso molecular:453.5CTA 056
CAS:<p>CTA 056 is an ITK inhibitor that inhibits the growth of MOLT-4 xenograft tumors in mice and can be used to study autoimmune disorders.</p>Fórmula:C35H34N6OPureza:97.22% - 97.76%Forma y color:SolidPeso molecular:554.68CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Fórmula:C25H24ClN7O2Pureza:99.66%Forma y color:SolidPeso molecular:489.96Tafetinib
CAS:<p>Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.</p>Fórmula:C24H29FN4O2Pureza:96.23%Forma y color:SolidPeso molecular:424.51EGFR-IN-11
CAS:<p>EGFR-IN-11 selectively blocks EGFR-tyrosine kinase and promotes apoptosis; targets EGFRL858R/T790M/C797S, IC50=18 nM; halts cell cycle at G0/G1.</p>Fórmula:C29H35N9O2SPureza:99.93%Forma y color:SolidPeso molecular:573.71BMS-605541
CAS:<p>BMS-605541 is a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity(Ki=49 nM).</p>Fórmula:C19H17F2N5OSPureza:98.07%Forma y color:SolidPeso molecular:401.43Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Forma y color:SoildPeso molecular:591.55JNJ-49095397
CAS:<p>JNJ-49095397 (RV568) is a p38 MAPK-α and p38 MAPK-γ kinase inhibitor for the study of respiratory syncytial virus infection.</p>Fórmula:C34H36N6O4Pureza:98.33% - 99.04%Forma y color:SolidPeso molecular:592.69HIF-2α-IN-3
CAS:<p>HIF-2α-IN-3 is an allosteric inhibitor of HIF-2α (IC50: 0.4 μM; KD: 1.1 μM) with anticancer activity.</p>Fórmula:C12H6ClN5O5Pureza:98.11%Forma y color:SolidPeso molecular:335.66WDR5-0102
CAS:<p>WDR5-0102 inhibits WDR5-MLL1 (Kd=4 μM), blocks MLL1 HMT activity, but doesn't affect SETD7 and 6 other HMTs.</p>Fórmula:C18H19ClN4O3Pureza:98.03%Forma y color:SolidPeso molecular:374.82STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Forma y color:SolidPeso molecular:318.76SI-2 hydrochloride
CAS:<p>SI-2 hydrochloride, an SRC-3 inhibitor, induces breast cancer cell death (IC50: 3-20 nM) with good oral bioavailability.</p>Fórmula:C15H16ClN5Pureza:98.6%Forma y color:SolidPeso molecular:301.77TC-S 7009
CAS:TC-S 7009: Strong HIF-2α inhibitor (Kd 81 nM), weak for HIF-1α; disrupts dimerization & gene expression.Fórmula:C12H6ClFN4O3Pureza:99.46% - 99.71%Forma y color:SolidPeso molecular:308.65c-Fms-IN-3
CAS:c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.Fórmula:C23H30N6OPureza:99.87%Forma y color:SolidPeso molecular:406.52Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Fórmula:C40H38ClNO5Pureza:99.97%Forma y color:SolidPeso molecular:648.19A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Forma y color:SolidPeso molecular:352.35Fenlean
CAS:"Fenlean (FLZ) in phase I trial at Chinese Academy's Institute of Pharmacy for Parkinson's treatment."Fórmula:C26H27NO6Pureza:98.99%Forma y color:SolidPeso molecular:449.5A 419259 trihydrochloride
CAS:A 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).Fórmula:C29H37Cl3N6OPureza:99.75% - 99.96%Forma y color:SolidPeso molecular:592PP58
CAS:PP58 is an inhibitor of PDGFR, FGFR and Src family.Fórmula:C22H19Cl2N5O2Pureza:99.21%Forma y color:SolidPeso molecular:456.32PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Forma y color:SolidPeso molecular:330.38NX-2127
CAS:<p>NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative</p>Fórmula:C39H45N9O5Pureza:99.07%Forma y color:SolidPeso molecular:719.83MBM-55
CAS:<p>MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM.</p>Fórmula:C28H27FN6O2Pureza:99.83%Forma y color:SolidPeso molecular:498.55TP0427736 hydrochloride
CAS:<p>TP0427736 hydrochloride is a novel and selective ALK5 inhibitor, capable of inhibiting Smad2/3 phosphorylation in A549 cells.</p>Fórmula:C14H11ClN4S2Pureza:98.99%Forma y color:SolidPeso molecular:334.85H-9 dihydrochloride
CAS:<p>H-9 dihydrochloride: Strong PKA inhibitor, curbs 5-HT response and EGF signaling, affects pharyngeal function.</p>Fórmula:C11H15Cl2N3O2SPureza:97.3%Forma y color:SolidPeso molecular:324.23Dasatinib hydrochloride
CAS:<p>Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).</p>Fórmula:C22H27Cl2N7O2SPureza:99.88% - 99.98%Forma y color:SolidPeso molecular:524.47Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Forma y color:Yellow Green Powder /Off-White SolidPeso molecular:202.17Larixol
CAS:<p>Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for</p>Fórmula:C20H34O2Pureza:98%Forma y color:SolidPeso molecular:306.48BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Fórmula:C29H34N8O3Forma y color:SolidPeso molecular:542.63FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Fórmula:C25H24N6O2SForma y color:SolidPeso molecular:472.56PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Forma y color:SolidPeso molecular:473.92EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Fórmula:C19H22Cl2N6OSForma y color:SolidPeso molecular:453.39FGFR-IN-4
CAS:<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Fórmula:C24H21N7O2Forma y color:SolidPeso molecular:439.47BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Fórmula:C29H26FN5O3Pureza:98%Forma y color:SolidPeso molecular:511.55PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Fórmula:C19H22ClN7O3Pureza:98%Forma y color:SolidPeso molecular:431.88MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Fórmula:C25H16ClF2N5O2Forma y color:SolidPeso molecular:491.88JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Fórmula:C26H29ClN8OForma y color:SolidPeso molecular:505.01HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Fórmula:C31H41N7O4Forma y color:SolidPeso molecular:575.7Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Fórmula:C13H19BrN4Pureza:99.34%Forma y color:SolidPeso molecular:311.22SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Fórmula:C28H35ClFN7O3SForma y color:SolidPeso molecular:604.14BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Forma y color:SolidPeso molecular:465.51BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Fórmula:C27H24ClF2N5O4Forma y color:SolidPeso molecular:555.96PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Fórmula:C27H34ClN7O3SForma y color:SolidPeso molecular:572.12EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Fórmula:C19H21N5O3Pureza:97.4%Forma y color:SolidPeso molecular:367.4TIE-2/VEGFR-2 kinase-IN-3
CAS:<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Fórmula:C23H17F4N5O3SForma y color:SolidPeso molecular:519.4710Z-Hymenialdisine
CAS:<p>Pan kinase inhibitor</p>Fórmula:C11H10BrN5O2Pureza:98%Forma y color:Light Yellow SolidPeso molecular:324.13Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Fórmula:C25H26ClFN4O4Pureza:99.7%Forma y color:SolidPeso molecular:500.95JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Forma y color:SolidPeso molecular:684.69Henatinib
CAS:<p>Henatinib: orally active multi-kinase inhibitor targeting VEGFR-2, c-kit, PDGFR with antitumor effects.</p>Fórmula:C25H29FN4O4Forma y color:SolidPeso molecular:468.52BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Forma y color:SolidPeso molecular:567.01JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Fórmula:C33H34N8O2Forma y color:SolidPeso molecular:574.68BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Forma y color:SolidPeso molecular:457.36T338C Src-IN-1
CAS:T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).Fórmula:C17H20N6O2SPureza:98%Forma y color:SolidPeso molecular:372.44EGFR kinase inhibitor 1
CAS:<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Fórmula:C30H31N7O2Forma y color:SolidPeso molecular:521.61UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Fórmula:C30H44N6OForma y color:SolidPeso molecular:504.71SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Fórmula:C51H66N10O7S2Forma y color:SolidPeso molecular:995.26JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Fórmula:C26H27Cl2N5O2Pureza:98%Forma y color:SolidPeso molecular:512.43FGFR-IN-2
CAS:<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Fórmula:C25H30N6O2Forma y color:SolidPeso molecular:446.54EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PForma y color:SolidPeso molecular:610.49SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Fórmula:C18H19NO5Pureza:98%Forma y color:SolidPeso molecular:329.35FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Fórmula:C25H22N4O5Forma y color:SolidPeso molecular:458.47Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39
